Pancreatic Cancer Initial Detection Via Liquid Biopsy

Sponsor
Karolinska University Hospital
Study ID
NCT06283576
Status
Enrolling By Invitation

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Accepted

Interventions

  • Liquid biopsy — DIAGNOSTIC_TEST
    Blood will be drawn upon clinical diagnosis / prior to biopsy/surgical resection for "ground truth"

Study Details

The overall rationale of PANCAID is to provide a diagnostic blood test for early diagnosis of pancreatic cancer. With a set of different liquid biopsy methods, it is the aim to measure these markers in well-defined patient cohorts. For the entire series of these studies, the following groups are planned: 1) Histologically proven early-stage pancreatic cancer (e.g. T1a/b and T2 carcinomas \[N0M0\]); 2) Intraductal papillary mucinous neoplasia (IPMN) that were operated with verification of the benign, premalignant or malignant histology; 3) ordinary branched-duct IPMN; 4) individuals at risk (IAR) with and without IPMN, with and without known hereditary cancer gene (e.g. BRCA2); 5) a high risk group of patients with chronic pancreatitis, aged 55-65, who are heavy smokers (≥40 PY), with newly onset diabetes mellitus (NODM).

Key Dates

First listed
Feb 28, 2024
Start date
May 1, 2024
Status verified
Apr 2024
Primary completion
Dec 31, 2027
Completion
Dec 31, 2027

Study Design

Enrollment
200 participants (estimated)

Arms

  • Arm: Pancreatic cancer, early
    Early pancreatic cancer, T1/T2 NoM0
  • Arm: IPMN
  • Arm: Pancreatic cancer, advanced
    Advance pancreatic cancer T1-4, Nx, Mx
  • Arm: Healthy controls

Primary Outcome Measure

Cancer detection [ Time Frame: Up to 4 weeks after surgery ]

Find similar trials

Nationwide
Pancreatic cancer trialsOncology trialsGI oncology trials

Related Studies